These tetramer products are for detection of CEF virus-specific T cells
The CEF peptide pool was initially described by Currier and include a well-defined set of 23 virus-derived peptides from Cytomegalovirus (C), Epstein Bar virus (E) and Influenza (Flu, F) viruses. The CEF peptide pool is extensively used as a positive control for CD8 T cell activation.
Peptides from the CEF pool causes CD8+ T cells to produce various cytokines including IFN-γ and is recommended as a positive control in IFN-γ ELISpot assays using human peripheral blood mononuclear cells (PBMC). The CEF pool has been shown to induce IFN-γ responses in up to 90% of all Caucasians.
CEF virus-specific CD8+T cells can be detected in preparations of lymphoid cells from infected individuals by staining with virus-specific Tetramers followed by flow cytometry analysis. Amongst the original 23 described virus peptides in the CEF pool are 4 peptide antigens frequently detected in humans using tetramer assays.
>> Order CEF virus-specific Tetramers to monitor CEF response
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-010 | HLA-A*02:01 | NLVPMVATV | HCMV pp65 495-504 |
| HA02-012 | HLA-A*0201 | GILGFVFTL | Influenza A MP 58-66 |
| HA02-011 | HLA-A*0201 | GLCTLVAML | EBV BMLF-1 259-267 |
| HB07-009 | HLA-B*0702 | RPPIFIRRL | EBV EBNA-3A 247-255 |
>> Order negative control Tetramers
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-179 | HLA-A*0201 | ALAAAAAAV | Control |
| HA02-024 | HLA-A*0201 | AVIAPVHAV | Control |
>>Other virus-specific Tetramers not included in the CEF pool
| Cat. No. | HLA type | Pep. Seq. | Antigen |
| HA02-028 | HLA-A*02:01 | VLEETSVML | HCMV IE1 316-324 (UL123) |
| HB07-015 | HLA-B*07:02 | TPRVTGGGAM | HCMV pp65 417-426 |
| HB07-008 | HLA-B*07:02 | RPHERNGFTVL | HCMV pp65 265-275 |
| HA24-013 | HLA-A*24:02 | QYDPVAALF | HCMV pp65 341-349 |
| HA24-021 | HLA-A*24:02 | VYALPLKML | HCMV pp65 113-121 |
| HA02-016 | HLA-A*02:01 | CINGVCWTV | HCV NS3 1073-1081 |
| HA02-017 | HLA-A*02:01 | CLGGLLTMV | EBV LMP-2 426-434 |
| HA02-015 | HLA-A*02:01 | FLPSDFFPSV | HBV Core antigen 18-27 |
| HA02-026 | HLA-A*02:01 | FLYALALLL | EBV LMP-2 356-364 |
| HA02-018 | HLA-A*02:01 | ILKEPVHGV | HIV-1 RT 476-484 |
| HA02-013 | HLA-A*02:01 | LLMWEAVTV | VP1 BK virus |
| HA02-014 | HLA-A*02:01 | SLYNTVATL | HIV-1 gag p17 76-84 |
| HA02-022 | HLA-A*02:01 | YMLDLQPET | HPV 16 E7 11-19 |
| HA02-027 | HLA-A*02:01 | YVLDHLIVV | EBV BRLF1 109–117 |
Clinical relevance of CEF virus-specific Tetramers
More than 90% of the world population is or have been infected with CMV, EBV or influenza virus.
Virus infections and in particular latent virus represent a health risk for immunocompromised patients in lack of a sufficiently effective population of virus-specific T cells.
Patients in risk of virus outbreak include allogenic stem cell or organ transplant patients, AIDS/HIV patients, elderly or neonatal patients. Monitoring virus-specific CD8+ T cells can predict the immune status in immunocompromised individuals. Virus-specific Tetramers can also be used for evaluating efficacy of virus-specific vaccines.
Advantages of virus-specific Tetramer assays.
Viral detection based on PCR and antigen-detection can examine viral burden and identify a reactivation of latent virus. However, these assays cannot assess the patients’ capability to respond to virus since these assays give no information regarding the existence of virus-specific T cells. CD8+ T cells are the main control against viral infection and adequate levels of virus-specific CD8 T cells are known to defend against viral disease.
Application of Tetramers
Tetramers are useful for detection, enumeration and isolation of virus-specific CD8+ T cells in a variety of Research Use Only (RUO) applications. Please check our standard protocols.
Tetramer specification
Tetramer Store supply MHC Tetramers in various test sizes and the colors PE, BV421, BUV395, APC-Cy™7, APC, BV510, BV480, PE-Cy™5, PE-CF594, PE-Cy™7, PerCP-Cy™5.5, PerCP, FITC, BV605, BV650, BV786, APC-R700, BB515 and BUV737. For other colors, please enquire.